Evaluation of Efficacy, Safety, and Withdrawal Period of Enrofloxacin (ENR) in Black Rockfish (Sebastes schlegelii) for Possible Treatment of Bacterial Diseases Caused by Streptococcus iniae and Aeromonas salmonicida
Abstract
Although enrofloxacin (ENR) is an important pharmaceutical in aquaculture for its excellent efficacy, it is mostly utilized through an off‐label prescription system. Thus, the optimal clinical use regimen is not well‐established. A series of studies was performed to obtain pharmacological and safety data needed for the use of ENR, a synthetic fluoroquinolone, in treating bacterial diseases occurring in black rockfish, Sebastes schlegelii. Minimal inhibitory concentrations showed that ENR exerts a potent in vitro efficacy inhibiting the growth of several pathogenic bacteria at concentrations less than 1 mg/L. ENR with oral doses of 5 mg/kg and up for 1 week significantly prevented mortality of black rockfish infected with Streptococcus iniae and Aeromonas salmonicida, demonstrating in vivo efficacy. Complete protection was obtained against these two bacteria by 10 mg/kg ENR in this in vivo infection trial. Black rockfish did not exhibit any severe abnormal signs by ENR up to 20 mg/kg when assessed by basic haematoclinical and histopathological parameters. Efficacy and toxicity study results collectively suggest that oral dose of 10 mg/kg ENR is optimal to treat bacterial infections. Through muscle residue analyses, the required withdrawal period for safe fish consumption was found to be approximately 90 days by measuring clearance of ENR and its metabolite ciprofloxacin (CIP). This study provides necessary information for the use of ENR to treat two frequently‐occurring…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
- Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.